Icad Inc (ICAD)

$1.52

-0.02

(-1.3%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Icad Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 4.07M → 4.74M (in $), with an average increase of 14.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -3.77M → 1.36M (in $), with an average increase of 114.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 24.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 57.6% return, outperforming this stock by 149.3%

Performance

  • $1.45
    $1.57
    $1.52
    downward going graph

    4.61%

    Downside

    Day's Volatility :7.64%

    Upside

    3.18%

    downward going graph
  • $1.05
    $3.97
    $1.52
    downward going graph

    30.92%

    Downside

    52 Weeks Volatility :73.55%

    Upside

    61.71%

    downward going graph

Returns

PeriodIcad IncSector (Health Care)Index (Russel 2000)
3 Months
-1.3%
-0.7%
0.0%
6 Months
0.0%
9.2%
0.0%
1 Year
4.83%
3.5%
-1.3%
3 Years
-91.8%
12.3%
-22.1%

Highlights

Market Capitalization
40.6M
Book Value
$1.27
Earnings Per Share (EPS)
-0.27
PEG Ratio
-0.56
Wall Street Target Price
4.83
Profit Margin
-27.99%
Operating Margin TTM
-15.13%
Return On Assets TTM
-10.32%
Return On Equity TTM
-20.52%
Revenue TTM
17.3M
Revenue Per Share TTM
0.68
Quarterly Revenue Growth YOY
2.3%
Gross Profit TTM
20.1M
EBITDA
-7.3M
Diluted Eps TTM
-0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.23
EPS Estimate Next Year
-0.18
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Icad Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 217.76%

Current $1.52
Target $4.83

Company Financials

FY18Y/Y Change
Revenue
25.6M
↓ 8.83%
Net Income
-9.0M
↓ 36.75%
Net Profit Margin
-35.19%
↑ 15.54%
FY19Y/Y Change
Revenue
31.3M
↑ 22.32%
Net Income
-13.6M
↑ 50.28%
Net Profit Margin
-43.24%
↓ 8.05%
FY20Y/Y Change
Revenue
29.7M
↓ 5.24%
Net Income
-17.6M
↑ 29.95%
Net Profit Margin
-59.3%
↓ 16.06%
FY21Y/Y Change
Revenue
33.6M
↑ 13.27%
Net Income
-11.2M
↓ 36.14%
Net Profit Margin
-33.43%
↑ 25.87%
FY22Y/Y Change
Revenue
27.9M
↓ 16.93%
Net Income
-13.7M
↑ 21.44%
Net Profit Margin
-48.87%
↓ 15.44%
FY23Y/Y Change
Revenue
17.3M
↓ 38.03%
Net Income
-7.4M
↓ 45.53%
Net Profit Margin
-42.96%
↑ 5.91%
Q3 FY22Q/Q Change
Revenue
6.4M
↓ 16.09%
Net Income
-3.8M
↑ 22.87%
Net Profit Margin
-60.35%
↓ 19.14%
Q4 FY22Q/Q Change
Revenue
6.5M
↑ 2.09%
Net Income
-3.1M
↓ 19.32%
Net Profit Margin
-47.7%
↑ 12.65%
Q1 FY23Q/Q Change
Revenue
5.8M
↓ 10.96%
Net Income
-3.8M
↑ 22.07%
Net Profit Margin
-65.39%
↓ 17.69%
Q2 FY23Q/Q Change
Revenue
5.9M
↑ 1.51%
Net Income
-1.8M
↓ 53.68%
Net Profit Margin
-29.84%
↑ 35.55%
Q3 FY23Q/Q Change
Revenue
4.1M
↓ 30.55%
Net Income
-1.4M
↓ 21.49%
Net Profit Margin
-33.73%
↓ 3.89%
Q4 FY23Q/Q Change
Revenue
4.7M
↑ 16.4%
Net Income
1.4M
↓ 199.13%
Net Profit Margin
28.73%
↑ 62.46%
FY18Y/Y Change
Total Assets
31.7M
↓ 1.23%
Total Liabilities
24.8M
↑ 39.13%
FY19Y/Y Change
Total Assets
41.7M
↑ 31.54%
Total Liabilities
36.7M
↑ 47.65%
FY20Y/Y Change
Total Assets
55.6M
↑ 33.14%
Total Liabilities
25.1M
↓ 31.68%
FY21Y/Y Change
Total Assets
62.2M
↑ 11.89%
Total Liabilities
15.7M
↓ 37.45%
FY22Y/Y Change
Total Assets
51.7M
↓ 16.86%
Total Liabilities
16.8M
↑ 7.2%
FY23Y/Y Change
Total Assets
41.4M
↓ 19.9%
Total Liabilities
8.0M
↓ 52.38%
Q3 FY22Q/Q Change
Total Assets
55.4M
↓ 5.15%
Total Liabilities
17.7M
↑ 1.88%
Q4 FY22Q/Q Change
Total Assets
51.7M
↓ 6.63%
Total Liabilities
16.8M
↓ 5.15%
Q1 FY23Q/Q Change
Total Assets
47.5M
↓ 8.1%
Total Liabilities
15.8M
↓ 5.92%
Q2 FY23Q/Q Change
Total Assets
44.8M
↓ 5.65%
Total Liabilities
14.7M
↓ 7.28%
Q3 FY23Q/Q Change
Total Assets
45.8M
↑ 2.22%
Total Liabilities
14.8M
↑ 0.92%
Q4 FY23Q/Q Change
Total Assets
41.4M
↓ 9.62%
Total Liabilities
8.0M
↓ 45.91%
FY18Y/Y Change
Operating Cash Flow
-3.9M
↓ 47.29%
Investing Cash Flow
-316.0K
↓ 112.87%
Financing Cash Flow
7.0M
↑ 22.82%
FY19Y/Y Change
Operating Cash Flow
-7.1M
↑ 83.79%
Investing Cash Flow
-306.0K
↓ 3.16%
Financing Cash Flow
10.5M
↑ 51.0%
FY20Y/Y Change
Operating Cash Flow
-7.0M
↓ 1.72%
Investing Cash Flow
-474.0K
↑ 54.9%
Financing Cash Flow
19.3M
↑ 83.4%
FY21Y/Y Change
Operating Cash Flow
-9.4M
↑ 34.69%
Investing Cash Flow
-587.0K
↑ 23.84%
Financing Cash Flow
17.1M
↓ 11.59%
FY22Y/Y Change
Operating Cash Flow
-12.8M
↑ 35.94%
Investing Cash Flow
-534.0K
↓ 9.03%
Financing Cash Flow
354.0K
↓ 97.93%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.7M
↑ 3.55%
Investing Cash Flow
-100.0K
↓ 3.85%
Financing Cash Flow
161.0K
↑ 250.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.1M
↑ 18.03%
Investing Cash Flow
-122.0K
↑ 22.0%
Financing Cash Flow
21.0K
↓ 86.96%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.5M
↓ 51.17%
Investing Cash Flow
-122.0K
↑ 0.0%
Financing Cash Flow
-16.0K
↓ 175.98%
Q2 FY23Q/Q Change
Operating Cash Flow
-405.0K
↓ 73.49%
Investing Cash Flow
-221.0K
↑ 81.15%
Financing Cash Flow
46.0K
↓ 388.31%

Technicals Summary

Sell

Neutral

Buy

Icad Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Icad Inc
Icad Inc
-1.94%
0.0%
4.83%
-91.8%
-67.31%
Stryker Corporation
Stryker Corporation
-7.29%
23.47%
7.74%
21.88%
74.06%
Boston Scientific Corp.
Boston Scientific Corp.
0.06%
34.31%
31.15%
57.57%
87.6%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.75%
24.46%
-3.21%
-10.62%
42.46%
Abbott Laboratories
Abbott Laboratories
-2.98%
12.01%
-2.83%
-13.13%
43.98%
Medtronic Plc
Medtronic Plc
-3.21%
9.79%
-10.17%
-39.42%
-5.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Icad Inc
Icad Inc
NA
NA
-0.56
-0.23
-0.21
-0.1
NA
1.27
Stryker Corporation
Stryker Corporation
39.69
39.69
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.01
63.01
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.37
37.37
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
32.79
32.79
5.99
4.33
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.14
25.14
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Icad Inc
Icad Inc
Buy
$41.9M
-67.31%
NA
-27.99%
Stryker Corporation
Stryker Corporation
Buy
$124.6B
74.06%
39.69
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$99.1B
87.6%
63.01
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.7B
42.46%
37.37
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$182.7B
43.98%
32.79
13.96%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-5.32%
25.14
13.0%

Institutional Holdings

  • Portolan Capital Management, LLC

    4.68%
  • Vanguard Group Inc

    4.13%
  • Arnhold & S. Bleichroeder Advisers, LLC

    2.58%
  • Greenwood Capital Associates, LLC

    2.45%
  • Renaissance Technologies Corp

    1.98%
  • Granahan Investment Management Inc..

    1.62%

Corporate Announcements

  • Icad Inc Earnings

    Icad Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.

Organization
Icad Inc
Employees
67
CEO
Ms. Dana R. Brown
Industry
Electronic Technology

FAQs